Search clinical trials for: SF2a-TT15 Shigella Vaccine

Total 14 results

Institut Pasteur
Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaborators

Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Healthy

Kenya
Institut Pasteur

Completed

SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers

Shigellosis | Bacillary Dysentery

Israel
University of Maryland, Baltimore

Active, not recruiting

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

Shigella

United States
U.S. Army Medical Research and Development Command
U.S. Army Office of the Surgeon General

Completed

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

Shigellosis

United States
PATH

Withdrawn

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

Shigella Sonnei Dysenteries

United States
GlycoVaxyn AG

Completed

Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella

Shigellosis

Switzerland
GSK Vaccines Institute For Global Health S.r.l.

Completed

Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults

Shigellosis

United Kingdom
GSK Vaccines Institute For Global Health S.r.l.

Completed

A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.

Shigellosis

France
GlaxoSmithKline

Completed

A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study

Dysentery, Bacillary

France
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh

Completed

Shigella WRSS1 Vaccine Trial in Bangladesh

Diarrhea

Bangladesh
University of Maryland, Baltimore
PATH

Completed

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Shigella

United States
University of Maryland, Baltimore
PATH

Terminated

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

Shigella

United States
Eunice Kennedy Shriver National Institute of Child...
The Chaim Sheba Medical Center; Schneider Children's Medical Center, Israel

Completed

Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel

Shigellosis

Israel
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

Diarrhoea

Belgium, Kenya

3

Subscribe